ALKBH3 upregulation has been associated with poorer prognostic outcomes in several cancers, including non-small-cell lung cancer [51], pancreatic cancer [52], renal cell carcinoma [53], and hepatocellular carcinoma [54]. Here, ALKBH3 is linked to renal cell carcinoma.